Surmodics, Inc. (SRDX): Price and Financial Metrics
Surmodics, Inc. (SRDX)
Today's Latest Price: $38.12 USD
Updated Nov 23 4:00pm
Add SRDX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
SRDX Stock Summary
- SRDX's current price/earnings ratio is 66.63, which is higher than 86.94% of US stocks with positive earnings.
- For SRDX, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
- In terms of twelve month growth in earnings before interest and taxes, Surmodics Inc is reporting a growth rate of 220.49%; that's higher than 93.59% of US stocks.
- If you're looking for stocks that are quantitatively similar to Surmodics Inc, a group of peers worth examining would be INS, SILC, TNAV, SIMO, and KLIC.
- Visit SRDX's SEC page to see the company's official filings. To visit the company's web site, go to www.surmodics.com.
SRDX Stock Price Chart Interactive Chart >
SRDX Price/Volume Stats
| Current price | $38.12 | 52-week high | $49.00 |
| Prev. close | $37.21 | 52-week low | $22.06 |
| Day low | $36.98 | Volume | 41,864 |
| Day high | $38.32 | Avg. volume | 66,916 |
| 50-day MA | $39.07 | Dividend yield | N/A |
| 200-day MA | $39.15 | Market Cap | 518.66M |
Surmodics, Inc. (SRDX) Company Bio
SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.
SRDX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $38.12 | $13.58 | -63% |
We started the process of determining a valid price forecast for Surmodics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Surmodics Inc ranked in the 25th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for SRDX, they are:
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0.05% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -64% |
| 1% | -64% |
| 2% | -63% |
| 3% | -63% |
| 4% | -63% |
| 5% | -62% |
A, BIO, ILMN, VIVO, and XRAY can be thought of as valuation peers to SRDX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...